PANews reported on March 21 that YZi Labs announced on the X platform that Jane He has been appointed as its general partner to lead biotech investments and contribute to the company's broad strategy in the fields of AI and Web3. Jane's appointment comes at a time when YZi Labs has expanded its investment focus from Web3 to AI and biotech after its recent rebranding.
It is reported that before joining YZi Labs, Jane worked as an investor and COO of a Hong Kong hedge fund, focusing on growth investments in biotechnology and innovation-driven fields. Her investment portfolio and research cover cancer treatment (immunotherapy, cell therapy, antibody-drug conjugates), metabolic therapy (GLP-1 drugs for obesity and type 2 diabetes), oligonucleotide therapy (mRNA, siRNA, ASO), gene editing, sequencing and medical devices. She also actively explores opportunities in the intersection of AI and biotechnology. Jane has held a leadership position at PAAMCO Prisma, an alternative investment management company, responsible for managing its investments in other funds in Asia. Jane holds an MBA from Stanford University and graduated as an Arjay Miller Scholar.
